A phase II randomized, placebo-controlled, international, multi-center clinical study of Neuro-Cells in patients with sub-acute spinal cord injury
Latest Information Update: 11 Sep 2023
At a glance
- Drugs Autologous neuroregenerative stem cell therapy-Neuroplast (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
Most Recent Events
- 07 Sep 2023 Preliminary Results presented in in the Neuroplast Media Release.
- 07 Sep 2023 Status changed from recruiting to active, no longer recruiting according to Neuroplast media release.
- 07 Sep 2023 According to a Neuroplast media release, Primary outcomes expected in February 2024 and full study completion projected in August 2024